The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents.
Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that
credit: Top News
occur in young children with acute myelogenous leukemia (AML).
However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.